dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: 2.1.1.- Methyltransferases (type: enzyme)
Target: methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit

Ligand: STC-15 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.210000038146973 pIC50
Reference (Patent): Polyheterocyclic compounds as mettl3 inhibitors

Ligand: STM2457 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.769999980926514 pIC50
Reference (Journal): Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.
Published in: Nature

Ligand: UZH2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): 1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.
Published in: J Med Chem

Ligand: WD6305 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of a PROTAC degrader for METTL3-METTL14 complex.
Published in: Cell Chem Biol
Target family: 2.1.1.- Methyltransferases (type: enzyme)
Target: nicotinamide N-methyltransferase

Ligand: NNMT inhibitor 14 [PMID: 35904556] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Journal): Peptide-to-Small Molecule: A Pharmacophore-Guided Small Molecule Lead Generation Strategy from High-Affinity Macrocyclic Peptides.
Published in: J Med Chem

Ligand: NNMT inhibitor 14 [PMID: 35904556] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.960000038146973 pIC50
Reference (Journal): Peptide-to-Small Molecule: A Pharmacophore-Guided Small Molecule Lead Generation Strategy from High-Affinity Macrocyclic Peptides.
Published in: J Med Chem
Target family: 2.1.1.- Methyltransferases (type: enzyme)
Target: thymidylate synthetase

Ligand: capecitabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1998), EMA (2001)
Primary target: yes
Median affinity:  -
Reference (Journal): The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Published in: Oncologist

Ligand: capecitabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1998), EMA (2001)
Primary target: yes
Median affinity:  -
Reference (Journal): UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Published in: Clin Cancer Res

Ligand: raltitrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2009)
Primary target: no
Median affinity: 6.380000114440918 pKi
Reference (Journal): Syntheses and thymidylate synthase inhibitory activity of the poly-gamma-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino ]-2-thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates.
Published in: J Med Chem

Ligand: raltitrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2009)
Primary target: yes
Median affinity: 6.539999961853027 pIC50
Reference (Journal): Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Published in: Bioorg Med Chem

Ligand: plevitrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.359999656677246 pKi
Reference (Journal): Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
Published in: J Med Chem

Ligand: pemetrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2009)
Primary target: no
Median affinity: 6.960000038146973 pKi
Reference (Journal): Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Published in: Adv Enzyme Regul

Ligand: ONX-0801 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.920000076293945 pKi
Reference (Journal): BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Published in: Cancer Res
Target family: 2.1.1.- Protein arginine N-methyltransferases (type: enzyme)
Target: protein arginine methyltransferase 8

Ligand: MS049 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.800000190734863 pIC50
Reference (Journal): Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.
Published in: J Med Chem
Target family: 2.1.1.- Protein arginine N-methyltransferases (type: enzyme)
Target: protein arginine methyltransferase 5

Ligand: TNG908 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.520000457763672 pKd
Reference (Journal): Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers.
Published in: J Med Chem

Ligand: TNG908 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.720000267028809 pKd
Reference (Journal): Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers.
Published in: J Med Chem
Target family: 2.1.1.- Protein arginine N-methyltransferases (type: enzyme)
Target: protein arginine methyltransferase 6

Ligand: C21 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.059999942779541 pIC50
Reference (Journal): Activity-based protein profiling of protein arginine methyltransferase 1.
Published in: ACS Chem Biol

Ligand: EPZ020411 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pIC50
Reference (Journal): Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound.
Published in: ACS Med Chem Lett

Ligand: MS023 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.220000267028809 pKd
Reference (Journal): A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
Published in: ACS Chemical Biology

Ligand: MS023 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.100000381469727 pKi
Reference (Journal): A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
Published in: ACS Chemical Biology

Ligand: MS049 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.059999942779541 pKd
Reference (Journal): Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.
Published in: J Med Chem

Ligand: MS049 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.369999885559082 pIC50
Reference (Journal): Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.
Published in: J Med Chem

Ligand: SGC6870 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.110000133514404 pIC50
Reference (Journal): A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6.
Published in: J Med Chem
Target family: 2.1.1.- Protein arginine N-methyltransferases (type: enzyme)
Target: protein arginine methyltransferase 7

Ligand: DS-437 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.21999979019165 pIC50
Reference (Journal): Discovery of a Dual PRMT5-PRMT7 Inhibitor.
Published in: ACS Med Chem Lett
Target family: 2.1.1.- Protein arginine N-methyltransferases (type: enzyme)
Target: protein arginine methyltransferase 8

Ligand: MS023 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.890000343322754 pKi
Reference (Journal): A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
Published in: ACS Chemical Biology
Target family: 2.1.1.- Protein arginine N-methyltransferases (type: enzyme)
Target: protein arginine methyltransferase 5

Ligand: TNG908 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers.
Published in: J Med Chem

Ligand: PF-06939999 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
Published in: Mol Cancer Ther

Ligand: onametostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pKd
Reference (Journal): Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
Published in: Mol Cancer Ther

Ligand: MRTX1719 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.850000381469727 pKd
Reference (Journal): Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted Cancers.
Published in: J Med Chem

Ligand: MRTX1719 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted Cancers.
Published in: J Med Chem

Ligand: LLY-283 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Webpage): LLY-283 A Chemical Probe For PRMT5.

Ligand: GSK591 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.960000038146973 pIC50
Reference (Webpage): GSK591 A chemical probe for PRMT5

Ligand: EPZ015666 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.300000190734863 pKi

Ligand: DS-437 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.230000019073486 pIC50
Reference (Journal): Discovery of a Dual PRMT5-PRMT7 Inhibitor.
Published in: ACS Med Chem Lett

Ligand: cmp5 [PMID: 25742700] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Published in: Blood
Target family: 2.1.1.- Protein arginine N-methyltransferases (type: enzyme)
Target: protein arginine methyltransferase 3

Ligand: SGC707 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: yes
Median affinity: 7.28000020980835 pKd
Reference (Journal): A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3).
Published in: Angew Chem Int Ed Engl

Ligand: MS023 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.260000228881836 pKi
Reference (Journal): A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
Published in: ACS Chemical Biology

Ligand: compound 1 [PMID: 22795084] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): An allosteric inhibitor of protein arginine methyltransferase 3.
Published in: Structure
Target family: 2.1.1.- Protein arginine N-methyltransferases (type: enzyme)
Target: protein arginine methyltransferase 1

Ligand: RM65 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.260000228881836 pIC50
Reference (Journal): A novel arginine methyltransferase inhibitor with cellular activity.
Published in: Bioorg Med Chem Lett

Ligand: MS023 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.960000038146973 pKi
Reference (Journal): A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
Published in: ACS Chemical Biology

Ligand: C21 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.739999771118164 pIC50
Reference (Journal): Activity-based protein profiling of protein arginine methyltransferase 1.
Published in: ACS Chem Biol

Ligand: AMI-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.059999942779541 pIC50
Reference (Journal): Small molecule regulators of protein arginine methyltransferases.
Published in: J Biol Chem
Target family: 2.1.2.- Hydroxymethyl-, formyl- and related transferases (type: enzyme)
Target: phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase

Ligand: pemetrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2009)
Primary target: no
Median affinity: 5.03000020980835 pKi
Reference (Journal): Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Published in: Adv Enzyme Regul
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: lysine acetyltransferase 2B

Ligand: anacardic acid (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.070000171661377 pIC50

Ligand: compound 1 [PMID: 15724976] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.289999961853027 pIC50
Reference (Journal): Selective small molecules blocking HIV-1 Tat and coactivator PCAF association.
Published in: J Am Chem Soc

Ligand: garcinol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.300000190734863 pIC50
Reference (Journal): Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression.
Published in: J Biol Chem

Ligand: epigallocatechin-3-gallate (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.21999979019165 pIC50
Reference (Journal): Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation.
Published in: Cancer Res

Ligand: H3-CoA-20 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pIC50
Reference (Journal): HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF.
Published in: Mol Cell
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: nuclear receptor coactivator 3

Ligand: SI-10 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy.
Published in: J Med Chem
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: nuclear receptor coactivator 1

Ligand: compound 26 [PMID: 21733693] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.
Published in: Bioorg Med Chem Lett
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: lysine acetyltransferase 8

Ligand: PF-9363 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.170000076293945 pIC50
Reference (Journal): Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Published in: Cell Chem Biol

Ligand: MG149 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.329999923706055 pIC50
Reference (Journal): 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site.
Published in: Eur J Med Chem
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: lysine acetyltransferase 7

Ligand: PF-9363 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.150000095367432 pIC50
Reference (Journal): Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Published in: Cell Chem Biol
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: lysine acetyltransferase 6B

Ligand: PF-9363 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.619999885559082 pIC50
Reference (Journal): Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Published in: Cell Chem Biol
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: lysine acetyltransferase 6A

Ligand: PF-9363 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.569999694824219 pIC50
Reference (Journal): Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Published in: Cell Chem Biol
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: lysine acetyltransferase 5

Ligand: PF-9363 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.380000114440918 pIC50
Reference (Journal): Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Published in: Cell Chem Biol

Ligand: MG149 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.130000114440918 pIC50
Reference (Journal): 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site.
Published in: Eur J Med Chem
Target family: 2.3.1.48 Histone acetyltransferases (HATs) (type: enzyme)
Target: lysine acetyltransferase 2B

Ligand: plumbagin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.300000190734863 pIC50
Reference (Journal): Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin.
Published in: J Biol Chem

Ligand: MB-3 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4 pIC50
Reference (Journal): Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5.
Published in: Angew Chem Int Ed Engl

Ligand: Lys-CoA (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 3.700000047683716 pIC50
Reference (Journal): HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF.
Published in: Mol Cell

Ligand: LTK-14 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Specific inhibition of p300-HAT alters global gene expression and represses HIV replication.
Published in: Chem Biol
Target family: 2.3.1.-  Acyltransferases (type: enzyme)
Target: fatty acid synthase

Ligand: orlistat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999), EMA (1998)
Primary target: no
Median affinity: 5.869999885559082 pIC50
Reference (Journal): Synthesis of novel beta-lactone inhibitors of fatty acid synthase.
Published in: J Med Chem

Ligand: orlistat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999), EMA (1998)
Primary target: no
Median affinity: 6.550000190734863 pKi
Reference (Journal): The lipogenesis pathway as a cancer target.
Published in: J Med Chem

Ligand: GSK2194069 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.109999656677246 pIC50
Reference (Journal): A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site.
Published in: Nat Chem Biol
Target family: 2.3.1.-  Acyltransferases (type: enzyme)
Target: diacylglycerol O-acyltransferase 2

Ligand: PF-07202954 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-Life.
Published in: ACS Med Chem Lett

Ligand: ervogastat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.760000228881836 pIC50
Reference (Journal): Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
Published in: J Med Chem

Ligand: ervogastat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.079999923706055 pIC50
Reference (Journal): Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
Published in: J Med Chem